Navigation Links
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
Date:11/14/2009

The FDA is reviewing preliminary safety information on XOLAIR allergic asthma medication. Problems with XOLAIR have been linked to heart attack and stroke. The Onder Law Firm is offering a free case review to those or families of those who may have experienced serious health problems after taking XOLAIR.

St. Louis, MO (Vocus) November 14, 2009 -- The FDA is evaluating interim safety findings from Genentech, Inc. in an ongoing study of XOLAIR problems. XOLAIR (omalizumab) is an injected drug for asthma related allergies. The interim results of this study, which is being conducted by the drug’s manufacturer, suggests an increased number of cardiovascular (heart attack) and cerebrovascular (stroke) adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group).

The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The results this study are not expected until 2012. Although the FDA and the drug manufacturer have not recalled XOLAIR, the FDA wants consumers to be aware of increased risks from taking XOLAIR, specifically heart attack/heart disease and stroke.

The FDA originally approved XOLAIR in 2003 but announced in February of 2007 that it was requesting a stronger warning for XOLAIR because it may cause anaphylaxis, a reaction that may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat.

“It is important for persons who have used or are using XOLAIR to be aware of the side effects and hazards,” stated James Onder of Onder, Shelton, O’Leary & Peterson, LLC. The firm’s XOLAIR safety information web site contains information regarding XOLAIR side effects and the rights those suffering from them may have. The attorneys of The Onder Law Firm will review will provide free case review to persons having experienced side effects or medical problems after taking XOLAIR. The Onder Law Firm provides experienced legal representation without fee unless it collects for its clients.

About The Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O’Leary & Peterson has represented clients throughout the United States in pharmaceutical litigation such as Vioxx, Digitek, Ethex and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation. For more information, visit www.onderlaw.com or call 1-877-ONDER-LAW.

# # #

Read the full story at http://www.prweb.com/releases/xolair/safety/prweb3207784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. FDA Investigating Safety of Asthma Drug Xolair
2. FDA Questions Safety of Caffeinated Alcoholic Drinks
3. Centerplate and the Capital Improvement Board Investigating Food Safety Violations at Lucas Oil Stadium to Ensure Highest Standards Achieved and Operational Excellence
4. New Polls, Reports Highlight The Need To Update The U.S. Food Safety System And To Make Our Food Safe For The Holidays
5. New Research Center to Focus on Cardiac Safety and Innovation
6. New research center to focus on cardiac safety and innovation
7. Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety
8. Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Capnography Monitoring Significantly Improves Patient Safety during Procedural Sedation in the Emergency Department
10. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
11. Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
(Date:6/28/2017)... ... June 28, 2017 , ... ... communities throughout the greater Cincinnati metropolitan area, is teaming up with the local ... families with children receiving treatment in nearby hospitals. , Ronald McDonald House of ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: